Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

Synopsis

Nature Medicine, Published online: 02 November 2026; doi:10.1038/s41591-026-04739-2 In the STOP-V1 and STOP-V2 trials, povorcitinib (an oral JAK1 inhibitor) was superior to placebo in improvement in F-VASI75 score in individuals with nonsegmental vitiligo.

The publisher’s own description. This is a short summary, not the full story, and may omit important detail.